Skip to main content


Risk and protective genetic variants in suicidal behaviour: association with SLC1A2, SLC1A3, 5-HTR1B & NTRK2 polymorphisms



Suicidal behaviour is known to aggregate in families. Patients with psychiatric disorders are at higher risk for suicide attempts (SA), however protective and risk genetic variants for suicide appear to be independent of underlying psychiatric disorders. Here we investigate genetic variants in genes important for neurobiological pathways linked to suicidal behaviour and/or associated endophenotypes, for association with SA among patients with co-existing psychiatric illness. Selected gene-gene and gene-environment interactions were also tested.


DNA was obtained from bloods of 159 patients (76 suicide attempters and 83 non-attempters), who were profiled for DSM-IV Axis I psychiatric diagnosis. Twenty-eight single nucleotide polymorphisms (SNPs) from 18 candidate genes (COMT, 5-HT2A, 5-HT1A, 5-HTR1B, TPH1, MAO-A, TPH2, DBH, CNR1, BDNF, ABCG1, GABRA5, GABRG2, GABRB2, SLC1A2, SLC1A3, NTRK2, CRHR1) were genotyped. Genotyping was performed by KBioscience. Tests of association between genetic variants and SA were conducted using Chi squared and Armitage Trend tests. Binary logistical regression analyses were performed to evaluate the contribution of individual genetic variants to the prediction of SA, and to examine SNPs for potential gene-gene and gene-environment interactions.


Our analysis identified 4 SNPs (rs4755404, rs2269272, rs6296 and rs1659400), which showed evidence of association with SA compared to a non-attempter control group. We provide evidence of a 3-locus gene-gene interaction, and a putative gene-environment interaction, whereby genetic variation at the NTRK2 locus may moderate the risk associated with history of childhood abuse.


Preliminary findings suggest that allelic variability in SLC1A2/3, 5-HTR1B and NTRK2 may be relevant to the underlying diathesis for suicidal acts.


Suicide represents a worldwide public health problem and is a leading cause of death among those aged 15-44 years in many developed countries, representing a significant social and economic burden According to the stress-diathesis model of suicidal behaviour, risk of suicide is not exclusively determined by a psychiatric illness (or an alternative stressor), but rather that individuals may have a predisposition or tendency towards suicidal ideation, which is aggravated further by one or more stressors [1]. A greater understanding of clinical and biological risk factors will help us understand more fully this model of suicidal behaviour and inform new therapies and tailored interventions.

The molecular pathology of suicidal behaviour remains complex; epidemiological studies have demonstrated familial clustering of suicide and suicidal behaviour [2]. Meta-analysis of published twin case studies for suicide found a higher rate of concordance for suicide and for suicidal behaviour in monozygotic (MZ) versus dizygotic (DZ) twins, establishing a solid genetic link [3]. Currently, risk assessment of suicidal behaviour relies heavily on clinical variables [4]. Indeed, patients with psychiatric disorders are at higher risk for suicide attempt (SA) [58], however protective and risk genetic variants for suicide appear to be independent of underlying psychiatric disorders [911]. Identifying relevant genetic variants or single nucleotide polymorphisms (SNPs) in genes intimately linked to various neurobiological pathways, whose alteration may contribute to suicidal behaviour, may provide insight into the etiological processes that underlie suicidal behaviour and identify novel biological therapeutic targets.

Numerous neurobiological pathways have been implicated in the etiology of suicide and suicidal behaviour. Deregulation of the monoaminergic transmitter systems (norepinephrine, dopamine and serotonin) [12, 13], gamma aminobutyric acid (GABA) inhibitory neurotransmitter system [14, 15], glutamatergic excitatory neurotransmitter system [14, 15], lipid metabolism [16, 17], cannabinoid system [18] and neurotrophic signalling factors [19] are linked to suicidal behaviour. Interestingly, the hypothalamic-pituitary-adrenal (HPA) axis may be involved in increased suicidal behaviour in response to adversity during development [20], hence highlighting the contribution of early environmental factors to suicide risk.

Suicidal behaviour is a complex trait; therefore it is likely to be the result of a combination of numerous environmental and genetic factors with an added layer of complexity via potential gene-gene (GxG) and gene-environment (GxE) interaction effects [21]. Consequently, investigating the relationship between genetic variants and environmental factors (e.g. childhood abuse or alcoholism) is an important step towards elucidating the mechanisms behind suicidal behaviour.

Here we test the hypothesis that genetic variants in candidate genes important for neurobiological pathways linked to suicidal behaviour and/or associated endophenotypes, may confer a protective [22] or risk effect on SA among patients with co-existing psychiatric illness (suicide attempters versus non-attempter controls). In addition to main genetic effects, we also tested selected GxG and GxE interactions for association with SA.


Clinical sample collection

The study consisted of 159 psychiatric patients recruited as part of the Ireland North/South Urban/Rural Epidemiologic (INSURE) collaborative project [23]. Briefly, consecutive newly referred patients to six Community Psychiatric Clinics on the island of Ireland (Donegal, Belfast, Omagh, Dublin, Portlaoise and Ballinasloe) were invited to take part in a clinical and molecular genetics study of suicidal behaviour in major psychiatric disorders over a year long recruitment period. In total, 159 patients gave written informed consent for the study. Patients were interviewed for Axis I Psychiatric Disorders using the Structured Clinical Interview for DSM-IV [24]. History of attempted suicide was recorded using the Columbia University Suicide History Questionnaire [25], which incorporates the Scale for Suicide Ideation [26], and the Suicide Intent Scale [27]. A suicide attempt was defined as a completed act of self-harm with at least some expressed intent to die (scoring at least 1 on item 10 of Suicide Intent Scale [27]). Seventy-six (48% Male, 52% Female; Mean age: 34.7 yrs) had a history of SA and 83 (61.4% Male, 38.6% Female; Mean age: 40.7 yrs) had not. Childhood abuse was defined as the presence or absence of a history of sexual and/or physical abuse under the age of 16. Further clinical variables from clinical and demographic assessments are outlined in Table 1. All clinical research interviews were performed by a trained research psychiatrist or research psychiatric nurse. Ethics approval was obtained for the study from the St Vincent's Healthcare Group Ethics and Medical Research Committee.

Table 1 DSM-IV psychiatric diagnosis and clinical features of patient samples

Gene and SNP selection

In this study, genes intimately linked to numerous neurobiological pathways considered important for the pathogenesis of suicide and/or associated disorders or endophenotypes, were selected. Genes from the following pathways were considered, monoaminergic transmitter systems (norepinephrine, dopamine and serotonin), GABA inhibitory neurotransmitter system, glutamatergic excitatory neurotransmitter system, HPA axis and cannabinoid system. Genes important for cholesterol transport and neural growth and differentiation were also selected.

Twenty-eight SNPs from the 18 selected genes (COMT, 5-HT2A, 5-HT1A, 5-HTR1B, TPH1, MAO-A, TPH2, DBH, CNR1, BDNF, ABCG1, GABRA5, GABRG2, GABRB2, SLC1A2, SLC1A3, NTRK2, CRHR1) were included in our analysis. SNPs, within these 18 genes, were screened for known genetic associations with suicide, suicidal behaviour and/or associated endophenotypes using biomedical online resources PubMed and OMIM Priority was given to functional SNPs or SNPs within regulatory regions utilising online genetic databases ensembl and DbSNP


DNA was extracted from patient blood samples using standard techniques. Flanking SNP sequences were obtained from DbSNP and all genotyping assays were designed and validated by KBioscience (Hertfordshire, UK). Genotyping for SNP analysis was performed by KBioscience using the competitive allele specific PCR (KASP) chemistry coupled with a FRET-based genotyping system Genotyping data was viewed using SNPviewer (KBioscience, Hertfordshire, UK), allowing graphical viewing of the clusters that group the allele calls.

SNPs in linkage disequilibrium (LD) with SNPs of interest were identified using a combination of information from Ensembl and Haploview

Data analysis

Deviations from Hardy Weinberg Equilibrium (HWE) were calculated using the exact test implemented by SNP and Variation Suite (SVS) 7 software (Bozeman, MT 59718 USA;

Statistical tests of association examining the relationship between patient's alleles or genotype, at each of the 28 genetic loci, and suicide attempt were performed using Pearson's Chi-square test or Fisher's exact test (when counts are low). This analysis was performed both in SPSS and SNP and Variation Suite for verification purposes.

SNPs which showed a modest level of association in the original allelic and genotype tests of association (P < 0.1) and one SNP which showed a gender specific association with SA, were further analysed by applying four genotype models (Additive (XX = 0, XY = 1, YY = 2), Dominant (XX = 0, XY & YY = 1), Over-dominant (XX & YY = 0, XY = 1) and Recessive (XX & XY = 0, YY = 1); X = Major allele, Y = Minor allele). For all models, except the additive model, Pearson's Chi-square test of association was used. For the additive model an exact Armitage trend test was preformed. Binary logistical regression analyses were performed to evaluate the contribution of the genotype model associated with SA at each locus in the prediction of attempted suicide, correcting for potential confounders such as age, gender and certain psychiatric disorders and to interrogate associated SNPs for potential GxG and GxE interactions. Analysis of potential GxE interactions were applied to SNPs with evidence of association in at least one genetic model (n = 3) and to one SNP which showed evidence of association in a gender specific manner (n = 1) and not examined for all candidate SNPs listed in this study. In addition, GXG interactions analysis was performed on these 4 SNPs, which showed evidence of association with SA and not examined for all candidate SNP listed in this study.

A non-parametric Mann-Whitney test was used to calculate the difference in age between cases and controls. For all other comparisons of clinical and demographic variables a Fisher's exact test or Chi-squared test of association was used. All statistical analysis was performed on SPSS (PASW statistics 18, Chicago, Illinois, USA) and genotypic associations verified using SNP and Variation Suite (SVS) 7 software. For all tests, significance was ascribed at P < 0.05.


Clinical and psychological features of study population

The mean age of the suicide attempter and non-attempter groups was significantly different (34.72 years versus 40.67 years, respectively, (P = 0.017)). The SA group were more likely to have a diagnosis of major depressive disorder (P = 0.022), a positive first degree family history of attempted suicide (P = 0.014), and a history of child abuse (physical or sexual) (P = 0.047). No other demographic or clinical variables were statistically different between the two groups (Table 1).

Candidate gene selection

In this study, genes considered important in various neurobiological pathways associated with suicide and/or associated disorders or endophenotypes were chosen. Overall, 18 genes were selected for inclusion in our analysis. The majority of genes (n = 8; COMT, 5-HT2A, 5-HT1A, 5-HTR1B, TPH1, MAO-A, TPH2, DBH) are important for monoaminergic transmitter systems (norepinephrine, dopamine and serotonin). Key genes of the GABA inhibitory neurotransmitter system (n = 3; GABRA5, GABRB2, GABRB2), glutamatergic excitatory neurotransmitter system (n = 2; SLC1A2, SLC1A3), HPA axis (n = 1; CRHR1), cannabinoid system (n = 1; CNR1), cholesterol transport (n = 1; ABCG1), neural growth and differentiation (n = 2; BDNF & NTRK2) were also selected (see Additional File 1). In total, 28 SNPs present within our 18 candidate genes were identified. The majority of SNPs (24/28 SNPs) had previous evidence of association with suicidal behaviour and/or associated disorders or endophenotypes (see Additional File 1).

Genetic variants and suicide attempts

Results of basic allelic and genotypic tests of association for each SNP and SA are illustrated in Table 2. Basic allelic and genotypic association analyses revealed two significant associations with SA; rs4755404 (Intronic region of SLC1A2; P = 0.024: Chi-square test) and rs6296 (Promoter CpG island of 5-HTR1B; P = 0.047: Chi-square test) loci. In addition a third SNP, rs2269272 (3'untranslated region (UTR)) in SLC1A3; P = 0.075: Chi-square test), with a P value < 0.1 was chosen for further analyses. Next, four genotype models (Additive, Dominant, Over-Dominant and Recessive) were tested for association with attempter status at each locus (Table 3).

Table 2 Association of candidate markers
Table 3 Genotype frequencies and genetic models of association

Rs4755404 yielded evidence of association in an additive and dominant genotype model (P = 0.029: Exact Armitage Trends test; P = 0.026: Chi-square test, respectively), where patients with a G/C or G/G genotype were significantly more likely to be present in the SA group. Variation at the rs6296 locus was associated with SA in an over-dominant genotype model, whereby a heterozygote (C/G) genotype was more frequently present in patients in the SA group than non-attempter group (P = 0.028). Rs2269272 variants revealed evidence of association in a recessive genotype model (P = 0.042; Chi-square test), with the T/T genotype more frequent in the non-attempter group than attempter group (Table 3).

SNPs of interest were investigated for possible associations with other clinical variables illustrated in Table 1. SNP rs2269272 showed no evidence of association with other clinical variables in the study. A dominant genotype at the rs4755404 locus was associated with patients with a history of schizophrenia and other psychotic disorders (P = 0.012; Chi-square test). A recessive genotype at the rs6296 locus yielded an association with individuals who abuse/depend on alcohol (p = 0.035). Binary logistical regression analyses were performed to evaluate the contribution of individual risk/protective polymorphisms in the prediction of attempted suicide. After controlling for possible confounders such as age, gender, alcohol abuse/dependence (rs6296 only) and schizophrenia (rs4755404 only), rs2269272 recessive genotype model was no longer a significant predictor of SA (P0.121; Odds ratio (OR) = 0.83, 95% C.I: .022-1.563). Rs4755404 dominant genotype model and rs6296 over-dominant genotype model were still significant predictors of SA (P = 0.031; OR = 2.198; 95% CI 1.059-4.563 and P = 0.023; OR = 2.244; 95% CI 1.096-4.597, respectively).

Each locus was also analysed for deviations from HWE. Deviations from HWE were observed at the rs6296 locus in the non-attempter group (P = 0.004) and at rs2269272 locus in the non-attempter group (P = 0.014).

Genetic and environmental interaction analysis

Individual SNPs were analysed for evidence of gene by sex interaction, to identify possible sex-specific associations with SA. Two gene-sex interactions were observed. A sex by rs2269272 interaction was found where a T/T genotype was more frequent in non-attempter male SA group. A gene by sex interaction was also observed for an intronic SNP, rs1659400, in the NTRK2 gene. Controlling for age, a C/C genotype at this locus was a significant predictor of SA in females (P = 0.048; OR = 2.968; 95% C.I 1.01- 8.72).

Finally, we investigated the effect of susceptibility loci on suicide attempts by other susceptibility loci by examining various two and three way G×G interactions. Logistic regression was used to model SA risk as a function of the genotype models associated with SA at each locus and 2-locus and 3-locus G×G interactions (Table 4). Controlling for possible confounders, age, gender, alcohol abuse/dependence and schizophrenia, a 3-locus gene (G×G×G) interaction (rs6296 (C/G) × rs4755404 (C/G or G/G) × rs1659400 (C/C) was a significant predictor of SA (P = 0.046).

Table 4 Final gene by gene interaction model: Logistic regression analysis

To evaluate further the association between susceptibility genotypes only and environmental risk factors, logistic regression was used to model risk as a function of the genotype models associated with SA at each locus, environmental risk factors and their interaction. Results provide evidence of a possible G (C/C genotype) × E (history of childhood abuse (both physical and sexual)) interaction at the rs1659400 locus. Interestingly, rs1659400 was not associated with SA (p = 0.823, Chi-square), however when all variables (including gender and age) are entered into a logistic regression analysis, the G×E interaction term is close to significance (P = 0.056, Table 5). Moreover, since a C/C genotype was associated with female SA, a G×E interaction was examined in females only. A G×E interaction contributed to the predictive ability of the model (P = 0.054, Table 5), a trend which did not reach statistical significance. Taken together our results suggest that individuals who experienced childhood abuse (physical or sexual) and have a C/C genotype at the rs1659400 locus may be more susceptible to SA.

Table 5 Gene by environment interaction: Logistic regression analysis


We have identified 4 SNPs (rs4755404, rs2269272, rs6296 and rs1659400) in genes SLC1A2, SLC1A3, 5-HTR1B and NTRK2, respectively, which showed evidence of association with SA compared to a non-attempter psychiatric control group. At present, there is no published data on 3/4 of the genetic variants (rs4755404, rs2269272 and rs1659400) reported here and their association with suicide or SA. In addition, we identified a 3-locus (rs6296 (C/G) × rs4755404 (C/G or G/G) × rs1659400 (C/C)) G×G interaction, which was a significant predictor of SA, suggesting that variation in SLC1A2, 5-HTR1B and NTRK2 genes may contribute to the risk of SA independently, and in an interactive manner. This paper provides evidence for the first time of a putative G×E interaction, where genetic variation at the rs1659400 locus may moderate the risk associated with history of childhood abuse and subsequent suicidal acts.

SLC1A2 and SLC1A3 are glial high-affinity transporter molecules that regulate glutamate concentrations at synapses [15]. Aberrant expression of these key transporters could impair reuptake of glutamate, hence prolong synaptic activation and potentially lead to cytotoxic damage to neurons and glia [15]. SLC1A2 and SLC1A3 are downregulated in the brains of MDD patients compared to controls [28]. Moreover, decreased SLC1A3 expression has been observed in suicide brains [29].

In this study, the SLC1A2 gene variant, rs4755404, was associated with SA and schizophrenia and other psychotic disorders. Consistent with these findings, rs4755404 was previously associated with schizophrenia in a Japanese patient cohort [30]. In contrast, the SLC1A3 gene variant, rs2269272, was significantly associated with male non-attempters, where a gene-sex interaction was observed. The T/T genotype is absent from the attempter group and over-represented in the male non-attempter group, suggesting a T/T genotype may confer a protective effect on risk of SA, particularly in males with underlying psychiatric disorders. HWE analysis revealed that the control group was not in equilibrium for the rs2269272 locus, which is likely due to the fact that our control group is not "disease-free" but rather consists of individuals with underlying psychiatric conditions. However, the possibility that some other factor may be influencing the over-representation of T allele homozygotes in the non-attempter group cannot be ruled out. Therefore, further investigation in a larger cohort of patients is warranted. Taken together, our findings support the glial hypothesis of mood abnormalities [28] and concur with the literature on a putative role of glutamate dysregulation in suicidal behaviour.

The serotonin (5-HT) system is the most widely studied area of neurobiological suicide research [21]. Aberrant 5-HT receptor binding has been implicated in suicide and SA [12]. 5-HTR1B binding is decreased in the prefrontal cortex of suicide brains [31]. Previously a 5-HTR1B promoter CpG island genetic variant, rs6296, was associated with SA [32]. However, findings are inconsistent and a number of studies have found no evidence of association [33, 34]. Rs6296 has also been associated with substance use disorders, major depression and inconsistently with alcohol abuse [33, 35]. Here we report a significant association between the rs6296 locus and SA. In addition, persons with a C/G genotype and a history of abuse or dependence on alcohol were significantly associated with SA, but a gene × alcohol interaction was not evident, suggesting that they represent additive risk factors. These findings provide the impetus for future studies in a cohort of alcohol abuse/dependence patients to further understand the relevance of rs6296 genetic variants and SA in patients with a history of alcohol abuse/dependence.

NTRK2 (TRKB) encodes the receptor for BDNF. Aberrant neurotrophic signalling has been implicated in suicide risk by various studies [36, 37]. BDNF and NTRK2 mRNA and protein expression are reported downregulated in the prefrontal cortex and hippocampus of suicide victims compared to controls [36, 37]. The majority of studies have focused on functional BDNF variant, rs6265, which has been inconsistently implicated in suicide and MDD [38, 39]. In this study, we found no evidence of association between rs6265 and SA, consistent with a previous report [40]. Previously, a number of genetic variants within the NTRK2 gene have been associated with SA among depressed patients [41]. We observed a significant association with NTRK2 intronic genetic variant, rs1659404, and SA in females. Rs1659400 is in strong LD with several other SNPs within the NTRK1 gene, some of which have been implicated in alcohol dependence and depression [42, 43].

To date a number of gene × childhood adversity interactions have been reported in psychiatric patients [4446]. Childhood trauma (including abuse) has been reported to interact with low expressing 5-HTTLPR genotypes and moderate the risk of suicidal behaviour [47]. Recently, an interaction between child maltreatment and 5-HTT polymorphisms and suicidal ideation among children was described [48]. Here we report, for the first time, a possible moderation effect of a NTRK2 polymorphism on childhood abuse and risk for future suicidal acts. It is important to note that a history of childhood abuse was assessed in this study by a trained clinician as opposed to self-report questionnaires. Recent research has demonstrated that clinician ratings of developmental histories, such as childhood sexual and physical abuse, are in agreement with patient's self-reports and thus supports the validity of clinician reports for numerous clinical variables, including childhood abuse assessment [49]. Future studies could investigate the putative interaction of this genetic variant with childhood trauma score, which would include sexual, physical and emotional abuse and neglect. Such a study would provide a more comprehensive assessment of gene × childhood adversity interaction and risk for SA at this locus.

A number of limitations are apparent in the current study. Firstly, case/control samples were not age-matched, with the SA group having a significantly younger mean age. The SA group also contained a greater number of individuals with a family history of SA and a history of childhood abuse. In addition, rates of MDD diagnoses were different in SA and non-attempter psychiatric controls. However, the genetic variants identified in this study were not associated with either MDD, a family history of SA or abuse. Moreover, our sample size may have reduced power to detect small genetic effects, or alternative interactions between genetic and environmental risk factors. In this study, multiple testing correction, such as Bonferroni correction, was not applied. Bonferroni correction can be regarded as ultraconservative [50] and ignores the functional candidate gene study design utilised, which is likely to increase the prior probability of detecting an association. In addition, given our modest sample size, Bonferroni correction is likely to result in large type II error rates. Arguably the best solution to type I error is replication [50].


In conclusion, we have identified statistically as well as biologically significant genetic polymorphisms that may be relevant to the underlying diathesis for suicidal acts [1]. An understanding of the functional consequence of these SNPs from a neuropathological standpoint would be advantageous to advance our understanding of their role in SA. The SNP associations identified in this study, although modest, merit further investigation in a larger cohort of suicide attempters and may contribute to future meta-analysis of suicidal behaviour susceptibility loci. Moreover, follow-up research of the genetic susceptibly polymorphisms identified in this study may increase our understanding of the complex relationship of genetic and environmental factors in suicidal behaviour in major psychiatric disorders.

Contributions of Authors

TMM performed genetic and statistical analysis, interpretation of the data and drafted the manuscript. MR carried out blood collection and Clinical rating and contributed to study design. TF participated in the design of the study and helped to draft the manuscript. CK participated in the design of the study. RM participated in the design of the study. JO'G carried out blood collection and Clinical rating. EC participated in the design of the study. JB carried out blood collection and Clinical rating. MR carried out blood collection and Clinical rating. AJ participated in the design of the study. AM carried out blood collection and Clinical rating. NB carried out blood collection and Clinical rating. AC carried out blood collection and Clinical rating DL carried out Clinical rating. SB carried out Clinical rating. PT participated in statistical and genetic analysis and helped to draft the manuscript. AB extracted DNA and prepared sample for storage and genotyping. LQ participated in statistical analysis. LD participated in statistical and genetic analysis and helped to draft the manuscript. CK participated in the design of the study and help to draft the manuscript. KMM participated in the design of the study and help to draft the manuscript. All authors have read and approved the final manuscript.







Gamma Aminobutyric Acid






Hardy Weinberg Equilibrium


Ireland North/South Urban/Rural Epidemiologic


Linkage Disequilibrium




Odds Ratio


Suicide Attempts


Single Nucleotide Polymorphisms


SNP and Variation Suite


Untranslated Region


  1. 1.

    Mann JJ, Waternaux C, Haas GL, Malone KM: Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry. 1999, 156: 181-189.

  2. 2.

    Turecki G: Suicidal behavior: is there a genetic predisposition?. Bipolar Disord. 2001, 3: 335-349. 10.1034/j.1399-5618.2001.30608.x.

  3. 3.

    Roy A, Segal NL: Suicidal behavior in twins: a replication. J Affect Disord. 2001, 66: 71-74. 10.1016/S0165-0327(00)00275-5.

  4. 4.

    Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, Hegerl U, Lonnqvist J, Malone K, Marusic A, Mehlum L, Patton G, Phillips M, Rutz W, Rihmer Z, Schmidtke A, Shaffer D, Silverman M, Takahashi Y, Varnik A, Wasserman D, Yip P, Hendin H: Suicide prevention strategies: a systematic review. JAMA. 2005, 294: 2064-2074. 10.1001/jama.294.16.2064.

  5. 5.

    Kessler RC, Borges G, Walters EE: Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry. 1999, 56: 617-626. 10.1001/archpsyc.56.7.617.

  6. 6.

    Brent DA, Perper JA, Moritz G, Allman C, Friend A, Roth C, Schweers J, Balach L, Baugher M: Psychiatric risk factors for adolescent suicide: a case-control study. J Am Acad Child Adolesc Psychiatry. 1993, 32: 521-529. 10.1097/00004583-199305000-00006.

  7. 7.

    Myers K, McCauley E, Calderon R, Mitchell J, Burke P, Schloredt K: Risks for suicidality in major depressive disorder. J Am Acad Child Adolesc Psychiatry. 1991, 30: 86-94. 10.1097/00004583-199101000-00013.

  8. 8.

    Winokur G, Tsuang M: The Iowa 500: suicide in mania, depression, and schizophrenia. Am J Psychiatry. 1975, 132: 650-651.

  9. 9.

    Henriksson MM, Aro HM, Marttunen MJ, Heikkinen ME, Isometsa ET, Kuoppasalmi KI, Lonnqvist JK: Mental disorders and comorbidity in suicide. Am J Psychiatry. 1993, 150: 935-940.

  10. 10.

    Vijayakumar L, Rajkumar S: Are risk factors for suicide universal? A case-control study in India. Acta Psychiatr Scand. 1999, 99: 407-411. 10.1111/j.1600-0447.1999.tb00985.x.

  11. 11.

    Brent DA, Bridge J, Johnson BA, Connolly J: Suicidal behavior runs in families. A controlled family study of adolescent suicide victims. Arch Gen Psychiatry. 1996, 53: 1145-1152.

  12. 12.

    Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G: Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci. 1998, 18: 7394-7401.

  13. 13.

    Bach-Mizrachi H, Underwood MD, Tin A, Ellis SP, Mann JJ, Arango V: Elevated expression of tryptophan hydroxylase-2 mRNA at the neuronal level in the dorsal and median raphe nuclei of depressed suicides. Mol Psychiatry. 2008, 13 (507-513): 465-

  14. 14.

    Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V, Rehal S, Klempan T, Gratton A, Benkelfat C, Rouleau GA, Mechawar N, Turecki G: Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One. 2009, 4: e6585. 10.1371/journal.pone.0006585.

  15. 15.

    Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE, Akil H, Watson SJ, Jones EG: Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA. 2005, 102: 15653-15658. 10.1073/pnas.0507901102.

  16. 16.

    Gietl A, Giegling I, Hartmann AM, Schneider B, Schnabel A, Maurer K, Moller HJ, Rujescu D: ABCG1 gene variants in suicidal behavior and aggression-related traits. Eur Neuropsychopharmacol. 2007, 17: 410-416. 10.1016/j.euroneuro.2006.11.004.

  17. 17.

    De Berardis D, Conti CM, Serroni N, Moschetta FS, Carano A, Salerno RM, Cavuto M, Farina B, Alessandrini M, Janiri L, Pozzi G, Di Giannantonio M: The role of cholesterol levels in mood disorders and suicide. J Biol Regul Homeost Agents. 2009, 23: 133-140.

  18. 18.

    Calati R, Porcelli S, Giegling I, Hartmann AM, Moller HJ, De Ronchi D, Serretti A, Rujescu D: Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. J Psychiatr Res. 45: 309-321.

  19. 19.

    Ernst C, Deleva V, Deng X, Sequeira A, Pomarenski A, Klempan T, Ernst N, Quirion R, Gratton A, Szyf M, Turecki G: Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase B in the frontal cortex of suicide completers. Arch Gen Psychiatry. 2009, 66: 22-32. 10.1001/archpsyc.66.1.22.

  20. 20.

    McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, Turecki G, Meaney MJ: Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009, 12: 342-348. 10.1038/nn.2270.

  21. 21.

    Ernst C, Mechawar N, Turecki G: Suicide neurobiology. Prog Neurobiol. 2009, 89: 315-333. 10.1016/j.pneurobio.2009.09.001.

  22. 22.

    Malone KM, Oquendo MA, Haas GL, Ellis SP, Li S, Mann JJ: Protective factors against suicidal acts in major depression: reasons for living. Am J Psychiatry. 2000, 157: 1084-1088. 10.1176/appi.ajp.157.7.1084.

  23. 23.

    Bannan NMKM: Methodological Challenges and Potential Benefits from Clinical and Biological Research Studies of Suicidal Behaviour in Patients with Psychiatric Illness: Preliminary Evidence from the INSURE Project. Journal of Health Gain. 2002, 5: 12-16.

  24. 24.

    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 2000, Washington, DC: American Psychiatric Association, 4

  25. 25.

    Brodsky BS, Oquendo M, Ellis SP, Haas GL, Malone KM, Mann JJ: The relationship of childhood abuse to impulsivity and suicidal behavior in adults with major depression. Am J Psychiatry. 2001, 158: 1871-1877. 10.1176/appi.ajp.158.11.1871.

  26. 26.

    Beck AT, Steer RA, Ranieri WF: Scale for Suicide Ideation: psychometric properties of a self-report version. J Clin Psychol. 1988, 44: 499-505. 10.1002/1097-4679(198807)44:4<499::AID-JCLP2270440404>3.0.CO;2-6.

  27. 27.

    Beck AT, Beck R, Kovacs M: Classification of suicidal behaviors: I. Quantifying intent and medical lethality. Am J Psychiatry. 1975, 132: 285-287.

  28. 28.

    Coyle JT, Schwarcz R: Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry. 2000, 57: 90-93. 10.1001/archpsyc.57.1.90.

  29. 29.

    Kim S, Choi KH, Baykiz AF, Gershenfeld HK: Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex. BMC Genomics. 2007, 8: 413-10.1186/1471-2164-8-413.

  30. 30.

    Deng X, Shibata H, Ninomiya H, Tashiro N, Iwata N, Ozaki N, Fukumaki Y: Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia. BMC Psychiatry. 2004, 4: 21-10.1186/1471-244X-4-21.

  31. 31.

    Huang YY, Grailhe R, Arango V, Hen R, Mann JJ: Relationship of psychopathology to the human serotonin1B genotype and receptor binding kinetics in postmortem brain tissue. Neuropsychopharmacology. 1999, 21: 238-246. 10.1016/S0893-133X(99)00030-5.

  32. 32.

    New AS, Gelernter J, Goodman M, Mitropoulou V, Koenigsberg H, Silverman J, Siever LJ: Suicide, impulsive aggression, and HTR1B genotype. Biol Psychiatry. 2001, 50: 62-65. 10.1016/S0006-3223(01)01108-8.

  33. 33.

    Huang YY, Oquendo MA, Friedman JM, Greenhill LL, Brodsky B, Malone KM, Khait V, Mann JJ: Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. Neuropsychopharmacology. 2003, 28: 163-169. 10.1038/sj.npp.1300000.

  34. 34.

    Rujescu D, Giegling I, Sato T, Moller HJ: Lack of association between serotonin 5-HT1B receptor gene polymorphism and suicidal behavior. Am J Med Genet B Neuropsychiatr Genet. 2003, 116B: 69-71. 10.1002/ajmg.b.10732.

  35. 35.

    Lappalainen J, Long JC, Eggert M, Ozaki N, Robin RW, Brown GL, Naukkarinen H, Virkkunen M, Linnoila M, Goldman D: Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 populations. Arch Gen Psychiatry. 1998, 55: 989-994. 10.1001/archpsyc.55.11.989.

  36. 36.

    Dwivedi Y, Mondal AC, Rizavi HS, Conley RR: Suicide brain is associated with decreased expression of neurotrophins. Biol Psychiatry. 2005, 58: 315-324. 10.1016/j.biopsych.2005.04.014.

  37. 37.

    Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN: Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003, 60: 804-815. 10.1001/archpsyc.60.8.804.

  38. 38.

    Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, Schulze TG, Deschner M, Schmal C, Hofels S, Zobel A, Illig T, Propping P, Holsboer F, Rietschel M, Nothen MM, Cichon S: Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry. 2005, 58: 307-314. 10.1016/j.biopsych.2005.04.006.

  39. 39.

    Oswald P, Del-Favero J, Massat I, Souery D, Claes S, Van Broeckhoven C, Mendlewicz J: No implication of brain-derived neurotrophic factor (BDNF) gene in unipolar affective disorder: evidence from Belgian first and replication patient-control studies. Eur Neuropsychopharmacol. 2005, 15: 491-495. 10.1016/j.euroneuro.2005.01.001.

  40. 40.

    Kohli MA, Salyakina D, Pfennig A, Lucae S, Horstmann S, Menke A, Kloiber S, Hennings J, Bradley BB, Ressler KJ, Uhr M, Muller-Myhsok B, Holsboer F, Binder EB: Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients. Arch Gen Psychiatry. 2010, 67: 348-359. 10.1001/archgenpsychiatry.2009.201.

  41. 41.

    Kohli MA, Salyakina D, Pfennig A, Lucae S, Horstmann S, Menke A, Kloiber S, Hennings J, Bradley BB, Ressler KJ, Uhr M, Muller-Myhsok B, Holsboer F, Binder EB: Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients. Arch Gen Psychiatry. 67: 348-359.

  42. 42.

    Lin E, Hong CJ, Hwang JP, Liou YJ, Yang CH, Cheng D, Tsai SJ: Gene-gene interactions of the brain-derived neurotrophic-factor and neurotrophic tyrosine kinase receptor 2 genes in geriatric depression. Rejuvenation Res. 2009, 12: 387-393. 10.1089/rej.2009.0871.

  43. 43.

    Xu K, Anderson TR, Neyer KM, Lamparella N, Jenkins G, Zhou Z, Yuan Q, Virkkunen M, Lipsky RH: Nucleotide sequence variation within the human tyrosine kinase B neurotrophin receptor gene: association with antisocial alcohol dependence. Pharmacogenomics J. 2007, 7: 368-379. 10.1038/sj.tpj.6500430.

  44. 44.

    Gillespie NA, Whitfield JB, Williams B, Heath AC, Martin NG: The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. Psychol Med. 2005, 35: 101-111. 10.1017/S0033291704002727.

  45. 45.

    Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003, 301: 386-389. 10.1126/science.1083968.

  46. 46.

    Prathikanti S, Weinberger DR: Psychiatric genetics--the new era: genetic research and some clinical implications. Br Med Bull. 2005, 73-74: 107-122. 10.1093/bmb/ldh055.

  47. 47.

    Roy A, Hu XZ, Janal MN, Goldman D: Interaction between childhood trauma and serotonin transporter gene variation in suicide. Neuropsychopharmacology. 2007, 32: 2046-2052. 10.1038/sj.npp.1301331.

  48. 48.

    Cicchetti D, Rogosch FA, Sturge-Apple M, Toth SL: Interaction of child maltreatment and 5-HTT polymorphisms: suicidal ideation among children from low-SES backgrounds. J Pediatr Psychol. 2010, 35: 536-546. 10.1093/jpepsy/jsp078.

  49. 49.

    DeFife JA, Drill R, Nakash O, Westen D: Agreement between clinician and patient ratings of adaptive functioning and developmental history. Am J Psychiatry. 167: 1472-1478.

  50. 50.

    Turic D, Langley K, Williams H, Norton N, Williams NM, Moskvina V, Vanden Bree MB, Owen MJ, Thapar A, O'Donovan MC: A Family Based Study Implicates Solute Carrier Family 1-Member 3 (SLC1A3) Gene in Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry. 2005, 57: 1461-1466. 10.1016/j.biopsych.2005.03.025.

Download references


We acknowledge funding from the Craig-Dobbin Newman Fellowship in Mental Health Research and the Programme for Research in Third-Level Institutions (PRTCI) and statistical advice from the Centre for Support and Training in Analysis and Research (CSTAR), University College Dublin. We would like to acknowledge assistance from Aggie Boylan, Hammad Khan and Sharyn Carley.

Author information

Correspondence to Therese M. Murphy.

Additional information

Competing interests

The authors declare that they have no competing interests.

Electronic supplementary material

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Murphy, T.M., Ryan, M., Foster, T. et al. Risk and protective genetic variants in suicidal behaviour: association with SLC1A2, SLC1A3, 5-HTR1B & NTRK2 polymorphisms. Behav Brain Funct 7, 22 (2011).

Download citation


  • Childhood Abuse
  • Suicidal Behaviour
  • Binary Logistical Regression Analysis
  • Genotype Model
  • Rs6296 Locus